• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Microbiol Infect . Association between low response to rubella vaccination and reduced anti-SARS-CoV-2 immune response after vaccination with B

tetano

Editor, Senior Moderator
Clin Microbiol Infect


. 2022 Sep 20;S1198-743X(22)00475-X.
doi: 10.1016/j.cmi.2022.09.007. Online ahead of print.
Association between low response to rubella vaccination and reduced anti-SARS-CoV-2 immune response after vaccination with BNT162b2: A cross-sectional study


Kazuhiko Nakaharai[SUP] 1 [/SUP], Yasushi Nakazawa[SUP] 2 [/SUP], Yukie Mishima[SUP] 3 [/SUP], Mari Saito[SUP] 3 [/SUP], Yoichi Shinozaki[SUP] 3 [/SUP], Masaki Yoshida[SUP] 4 [/SUP]



Affiliations
Free PMC article

Abstract

Objectives: Some vaccinated individuals fail to acquire an adequate immune response against infection. We aimed to determine whether messenger-RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination could induce sufficient immune response against SARS-CoV-2 in low responders to other vaccinations.
Methods: Using data from healthcare workers who received two doses of the BNT162b2 vaccine (BioNTech, Pfizer), we conducted a single-centre cross-sectional study to determine whether low responders to measles, rubella, and hepatitis B virus (HBV) vaccinations could acquire sufficient antibodies after SARS-CoV-2 vaccination. From May 2021 to June 2021, participants were tested for anti-SARS-CoV-2 spike immunoglobulin G (anti-S IgG) antibody at least two weeks after the second dose of BNT162b2. The association between low response to measles, rubella, and HBV vaccinations and the post-vaccination anti-S IgG titre was evaluated using multivariable linear regression analysis.
Results: All 714 participants were positive for the anti-S IgG titre (≥50.0 AU/mL) after two doses of BNT162b2 (median: 7,126.8 AU/mL, interquartile range: 4,496.2-11,296.8). There were 323 (45.2%), 131 (18.3%), and 43 (6.0%) low responders to measles, rubella, and HBV vaccinations, respectively. In the multivariable linear regression analysis, low responders to rubella vaccination had a significantly low acquisition of anti-S IgG titre after two doses of the BNT162b2 vaccine (standardised coefficient β = -0.110: 95% confidence interval: -0.175 to -0.044).
Conclusions: Low response to rubella vaccination is a potential predictor of reduced response to SARS-CoV-2 vaccination. Further studies are needed to determine whether a low response to rubella vaccination is associated with the durability of SARS-CoV-2 vaccination-induced immune response.

Keywords: Antibody; BNT162b2; COVID-19; SARS-CoV-2; Vaccine; rubella.
 
Back
Top Bottom